Summit Therapeutics SMMT EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Summit Therapeutics’s 10-Q, filed August 6, 2024, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's EBITDA margin?
- Summit Therapeutics (SMMT) reported EBITDA margin of -267,925.5% in Q2 2023.
- How has Summit Therapeutics's EBITDA margin changed year-over-year?
- Summit Therapeutics's EBITDA margin decreased by 6829.4% year-over-year, from -3,866.5% to -267,925.5%.
- What is the long-term trend for Summit Therapeutics's EBITDA margin?
- Over 2 years (2020 to 2022), Summit Therapeutics's EBITDA margin has grown at a 29.3% compound annual growth rate (CAGR), from -6,004.8% to -10,046.2%.
- What does EBITDA margin mean?
- Operating cash profitability per sales dollar, before interest, taxes, and non-cash charges.
- How do you interpret EBITDA margin?
- Useful for comparing operating profitability across firms with different depreciation policies and leverage. High EBITDA margin alongside heavy capex can still mean weak free cash flow — pair it with FCF margin.
- How does EBITDA margin compare across companies?
- Widely used to compare capital-intensive businesses on a like-for-like basis. Less meaningful for banks and insurers.